Barclays
ARIA

Barclays’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Barclays’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-59,100
Closed -$735K – 7225
2016
Q4 		$735K Sell
59,100
-35,900
-38% -$432K ﹤0.01% 3027
2016
Q3 		$1.3M Buy
95,000
+42,900
+82% +$431K ﹤0.01% 2381
2016
Q2 		$385K Sell
52,100
-14,500
-22% -$109K ﹤0.01% 3420
2016
Q1 		$400K Sell
66,600
-59,000
-47% -$331K ﹤0.01% 3325
2015
Q4 		$754K Sell
125,600
-14,700
-10% -$96.5K ﹤0.01% 2857
2015
Q3 		$702K Sell
140,300
-25,600
-15% -$197K ﹤0.01% 3047
2015
Q2 		$1.33M Buy
165,900
+38,400
+30% +$340K ﹤0.01% 2623
2015
Q1 		$1.02M Sell
127,500
-470,100
-79% -$3.48M ﹤0.01% 2959
2014
Q4 		$3.59M Buy
597,600
+45,400
+8% +$284K ﹤0.01% 1989
2014
Q3 		$2.76M Sell
552,200
-671,000
-55% -$3.92M ﹤0.01% 2361
2014
Q2 		$7.34M Buy
1,223,200
+409,900
+50% +$2.82M 0.01% 1399
2014
Q1 		$6.51M Buy
813,300
+507,900
+166% +$3.96M 0.01% 1504
2013
Q4 		$1.83M Buy
305,400
+202,700
+197% +$1.09M ﹤0.01% 2770
2013
Q3 		$1.85M Buy
102,700
+16,500
+19% +$320K ﹤0.01% 2674
2013
Q2 		$1.51M Buy
+86,200
New +$1.53M ﹤0.01% 2853

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Barclays's ARIA Position: Q1 2017 in Review

Barclays sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 17,361 shares — an estimated $216K sold.

Barclays first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $11.6M in Q4 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Barclays reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Barclays sold 17,361 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $216K.
  • Barclays first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Barclays's Ariad Pharmaceuticals Inc position peaked at $11.6M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Barclays's 13F filing for Q1 2017, filed 15 May 2017.